Cambio interim report Q2 2025
During the second quarter we continued to execute on our strategy to enable tomorrow’s health and social care, today. The team delivered against key milestones in our largest programmes while strengthening our offering through focused innovation.
Within the Sussa collaboration, Region Västerbotten went live with Cambio COSMIC. As one of Northern Europe’s most important healthcare IT programmes, the implementation in the Sussa regions continues to demonstrate the scalability of our platform and the strength of our partnership model across regions.
Outside Sweden, we reached a planned milestone in Åland where the technical operating environment was delivered and accepted. This provides the foundation for the next phases of testing, training and deployment later in the year.
We also advanced our product strategy with the acquisition of Leapscribe, an ambient clinical documentation company whose AI assistant helps clinicians capture high-quality notes during patient consultations. Leapscribe will be woven into COSMIC and our broader portfolio over the coming quarters. Our focus is to embed AI, responsibly, into everyday workflows so clinicians spend more time with patients and less time on documentation. This includes ambient scribe and structured data capture that improves downstream analytics. Security, privacy and safety by design remain non-negotiable.
- Revenue amounted to 310.1 (297.2) MSEK in the second quarter, representing growth of 4.3%
- Adjusted EBITDA amounted to 11.2 (44.0) MSEK, representing growth of -74.5%
- Income before tax amounted to -73.9 (-35.6) MSEK
- Net income per share was negative (neg)
Read more in the full report.
Johannes Fabó
Chief Financial Officer
+46 730 599 368
johannes.fabo@cambio.se
Sanolium AB, parent of the Cambio Group (“Cambio” or “the Company”) operating entities, is an e-health company providing comprehensive IT solutions to improve healthcare and patient safety. Cambio is one of the largest suppliers in Scandinavia and a growing player in the European market, with more than 170,000 users across regions and municipalities, general and university hospitals, health centers and specialist units. Cambio has offices in Sweden, Denmark, United Kingdom and Sri Lanka.